Tomoki Naoe

Tomoki Naoe's AcademicInfluence.com Rankings

Tomoki Naoe

Philosophy

#6140

World Rank

#9122

Historical Rank

Logic

#3327

World Rank

#4466

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Tomoki Naoe's Degrees

Doctorate Medicine University of Tokyo
PhD Medical Science University of Tokyo

Why Is Tomoki Naoe Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Tomoki Naoe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. (2001) (906)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (2008) (894)
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. (1999) (822)
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. (1997) (772)
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. (1996) (666)
let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. (2006) (644)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines (2000) (501)
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product (1998) (499)
Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines (1997) (484)
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. (2006) (430)
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia (1997) (369)
EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. (2012) (344)
Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients (2007) (342)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. (2019) (319)
Decreased Expression of MicroRNA-143 and -145 in Human Gastric Cancers (2009) (304)
MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. (2006) (297)
Downregulation of microRNAs‐143 and ‐145 in B‐cell malignancies (2007) (296)
Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain (2002) (289)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis (2005) (283)
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. (2005) (278)
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. (2004) (255)
Role of anti-oncomirs miR-143 and -145 in human colorectal tumors (2010) (254)
Array-based genomic resequencing of human leukemia (2010) (251)
Presentation and management of intravascular large B-cell lymphoma. (2009) (245)
Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. (1996) (238)
MicroRNA-143 and -145 in colon cancer. (2007) (238)
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins (1996) (232)
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. (2008) (232)
Integrin Activation and Matrix Binding Mediate Cellular Responses to Mechanical Stretch* (2005) (229)
Epstein–Barr virus‐encoded poly(A)− RNA supports Burkitt's lymphoma growth through interleukin‐10 induction (2000) (228)
Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. (2011) (223)
Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. (2011) (219)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. (2009) (215)
Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. (2000) (207)
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients (2014) (205)
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission (2005) (198)
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. (2004) (193)
Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells (2015) (190)
Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. (1997) (188)
Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults (2016) (177)
Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. (2011) (174)
Safety and efficacy of autologous progenitor cell transplantation for therapeutic angiogenesis in patients with critical limb ischemia. (2007) (170)
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells. (2007) (167)
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. (2006) (160)
Identification of a Polymorphic Gene, BCL2A1, Encoding Two Novel Hematopoietic Lineage-specific Minor Histocompatibility Antigens (2003) (159)
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy (1999) (158)
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments] (1994) (149)
Arsenic induces apoptosis in B‐cell leukaemic cell lines in vitro: activation of caspases and down‐regulation of Bcl‐2 protein (1998) (139)
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia (2003) (138)
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia (2013) (138)
MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. (2011) (131)
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. (2011) (131)
Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. (2014) (131)
Molecular evolution of acute myeloid leukaemia in relapse: unstable N‐ras and FLT3 genes compared with p53 gene (1999) (128)
Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis (2000) (124)
Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome (2007) (117)
Transforming mutations of RAC guanosine triphosphatases in human cancers (2013) (113)
KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. (2009) (111)
Randomized study of individualized induction therapy with or without vincristine, and of maintenance—intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML‐87 study of the Japan adult leukemia study group (1993) (110)
Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. (2017) (110)
Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors (2002) (108)
Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice (2007) (108)
Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. (2002) (106)
Adipose tissue-derived mesenchymal stem cells facilitate hematopoiesis in vitro and in vivo: advantages over bone marrow-derived mesenchymal stem cells. (2010) (106)
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases (2013) (105)
Small‐molecule Hedgehog inhibitor attenuates the leukemia‐initiation potential of acute myeloid leukemia cells (2016) (99)
Central nervous system involvement in intravascular large B‐cell lymphoma: A retrospective analysis of 109 patients (2010) (99)
Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. (2010) (98)
Ectopic Expression of MAFB Gene in Human Myeloma Cells Carrying (14;20)(q32;q11) Chromosomal Translocations (2001) (98)
Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation (2003) (96)
Prospective monitoring of BCR‐ABL1 transcript levels in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia undergoing imatinib‐combined chemotherapy (2008) (95)
Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. (2006) (95)
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. (1996) (95)
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor (2000) (94)
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all‐trans retinoic acid (2000) (93)
BCR-ABL-transformed GMP as myeloid leukemic stem cells (2008) (92)
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. (2003) (91)
Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia (1993) (91)
BMI-1 is Highly Expressed in M0-Subtype Acute Myeloid Leukemia (2005) (88)
Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR–ABL-positive acute lymphoblastic leukemia (2011) (87)
Identification of non-coding RNAs embracing microRNA-143/145 cluster (2010) (87)
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. (2009) (85)
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. (2011) (85)
Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group (2014) (83)
Differential constitutive activation between STAT‐related proteins and MAP kinase in primary acute myelogenous leukaemia (1998) (82)
JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults (2007) (81)
FLT3 in Human Hematologic Malignancies (2002) (81)
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies (2015) (81)
Missense Mutations of the Glycoprotein (GP) Ibβ Gene Impairing the GPIb α/β Disulfide Linkage in a Family With Giant Platelet Disorder (1997) (78)
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. (2018) (78)
Nucleophosmin: A versatile molecule associated with hematological malignancies (2006) (74)
Solid tumors after hematopoietic stem cell transplantation in Japan: incidence, risk factors and prognosis (2005) (72)
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study (2018) (72)
Prognostic Significance of TEL/AML1 Fusion Transcript in Childhood B‐Precursor Acute Lymphoblastic Leukemia (1998) (72)
Molecular Evaluation of Endothelial Progenitor Cells in Patients With Ischemic Limbs: Therapeutic Effect by Stem Cell Transplantation (2004) (71)
Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. The Leukemia Study Group of the Ministry of Health and Welfare (Kouseisho). (1995) (71)
Tumor-suppressive microRNA-145 targets catenin δ-1 to regulate Wnt/β-catenin signaling in human colon cancer cells. (2013) (70)
Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia (2006) (69)
Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-regulation in acute promyelocytic leukemia (1997) (67)
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. (2013) (64)
Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia (2000) (64)
Targeted disruption of mouse ortholog of the human MYH9 responsible for macrothrombocytopenia with different organ involvement: hematological, nephrological, and otological studies of heterozygous KO mice. (2004) (64)
Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes (2006) (63)
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells (2005) (63)
Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). (1995) (63)
Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy (2002) (62)
Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy (2009) (60)
Prognostic Implication of FLT 3 and N-RAS Gene Mutations in Acute Myeloid Leukemia (1999) (60)
Gene mutations of acute myeloid leukemia in the genome era (2013) (59)
Bernard-Soulier syndrome Kagoshima: Ser 444-->stop mutation of glycoprotein (GP) Ib alpha resulting in circulating truncated GPIb alpha and surface expression of GPIb beta and GPIX. (1994) (58)
Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia (2009) (58)
Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype (2003) (58)
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy (2008) (58)
Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan (2004) (58)
Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD (2007) (57)
DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. (2013) (57)
Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. (2007) (57)
Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with Flt3 Mutation (2006) (57)
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. (2006) (57)
Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare. (1993) (56)
Chemically modified synthetic microRNA-205 inhibits the growth of melanoma cells in vitro and in vivo. (2013) (56)
CMC‐544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B‐cell chronic lymphocytic leukaemia and lymphoma (2009) (56)
Normal and oncogenic FLT3. (2004) (56)
CD56/NCAM-Positive Langerhans Cell Sarcoma: A Clinicopathologic Study of 4 Cases (2005) (56)
Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation (2014) (55)
Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation (2003) (53)
In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice (2001) (52)
GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese. (2005) (50)
Glycine to aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. (1990) (50)
Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy (2007) (50)
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG (2018) (49)
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. (2006) (49)
Effect of retinoic acid isomers on proliferation, differentiation and PML relocalization in the APL cell line NB4. (1995) (48)
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. (2014) (48)
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. (2015) (48)
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia (2017) (48)
FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy (2001) (48)
Trough plasma concentration of imatinib reflects BCR–ABL kinase inhibitory activity and clinical response in chronic‐phase chronic myeloid leukemia: A report from the BINGO study (2010) (48)
Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome (2008) (48)
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. (1994) (47)
Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease (2005) (47)
Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycin-induced lung damage. (2011) (47)
Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats (2005) (45)
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). (2013) (45)
Thrombosis from a prothrombin mutation conveying antithrombin resistance. (2012) (45)
Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. (2009) (45)
Acetylation of PML Is Involved in Histone Deacetylase Inhibitor-mediated Apoptosis* (2008) (45)
Rapid Screening of Leukemia Fusion Transcripts in Acute Leukemia by Real-time PCR (2002) (45)
Etoposide-related acute promyelocytic leukemia (1998) (45)
The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft‐versus‐host disease prophylaxis (2003) (44)
Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation (2012) (44)
Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells (2000) (44)
Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation (1999) (43)
Novel heterozygous missense mutation in the platelet glycoprotein Ibβ gene associated with isolated giant platelet disorder (2001) (43)
PML-Retinoic Acid Receptor α Inhibits PML IV Enhancement of PU.1-Induced C/EBPε Expression in Myeloid Differentiation (2007) (43)
Analysis of the joining sequences of the t(15;17) translocation in human acute promyelocytic leukemia: Sequence non‐specific recombination between the pml and rara genes within identical short stretches (1995) (43)
Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells (1999) (42)
Remission induction of acute promyelocytic leukemia by all-trans-retinoic acid: molecular evidence of restoration of normal hematopoiesis after differentiation and subsequent extinction of leukemic clone. (1992) (42)
Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. (2006) (41)
Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography (2008) (41)
Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia (2000) (41)
Sustained activation of c‐jun‐N‐terminal kinase plays a critical role in arsenic trioxide‐induced cell apoptosis in multiple myeloma cell lines (2006) (41)
cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. (1996) (41)
Cyclin C Regulates Human Hematopoietic Stem/Progenitor Cell Quiescence (2009) (41)
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL (2009) (40)
Clonal Analysis of Multiple Point Mutations in the N‐ras Gene in Patients with Acute Myeloid Leukemia (1993) (40)
Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study (2010) (40)
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study (2018) (40)
Epigenetic regulation of microRNA-128a expression contributes to the apoptosis-resistance of human T-cell leukaemia jurkat cells by modulating expression of fas-associated protein with death domain (FADD). (2014) (40)
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. (1998) (40)
Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders (1996) (39)
Correlation of c-myc expression with nuclear pleomorphism in human renal cell carcinoma. (1989) (39)
Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies (2017) (39)
Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia (2013) (39)
A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations (2007) (38)
Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at Exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's Lymphoma in Japanese (2004) (38)
TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways (2004) (38)
Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. (2018) (38)
Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells. (2016) (38)
Acute myeloid leukemia in older adults (2012) (37)
Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice (2006) (37)
FLT3 regulates β-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells (2007) (37)
Down-regulation of CD 20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies : its prevalence and clinical significance (2009) (37)
Dexamethasone Palmitate Ameliorates Macrophages-Rich Graft-versus-Host Disease by Inhibiting Macrophage Functions (2014) (36)
Clinical characteristics and prognostic implications of NPM 1 mutations in acute myeloid leukemia (2005) (36)
Antitumor effect of arsenic trioxide in murine xenograft model (2003) (36)
Phase I trial of volasertib, a Polo‐like kinase inhibitor, in Japanese patients with acute myeloid leukemia (2015) (36)
Retinoic acid syndrome in NOD/scid mice induced by injecting an acute promyelocytic leukemia cell line (2004) (36)
A Single Minor Histocompatibility Antigen Encoded by UGT2B17 and Presented by Human Leukocyte Antigen-A*2902 and -B*4403 (2007) (36)
Long‐term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study (2012) (35)
Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1 (2003) (35)
Long‐term outcomes for unselected patients with acute myeloid leukemia categorized according to the World Health Organization classification: a single‐center experience (2005) (35)
Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. (2020) (35)
Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia (2010) (35)
FLT3 mutations in acute myeloid leukemia. (2006) (34)
A UGT2B17‐positive donor is a risk factor for higher transplant‐related mortality and lower survival after bone marrow transplantation (2005) (34)
Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib (2012) (34)
Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT (2013) (34)
A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor (2011) (34)
Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts (2014) (34)
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation (1997) (34)
B Cell Receptor-ERK1/2 Signal Cancels PAX5-Dependent Repression of BLIMP1 through PAX5 Phosphorylation: A Mechanism of Antigen-Triggering Plasma Cell Differentiation (2012) (33)
GATA-1 and GATA-2 binding to 3′ enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines (2009) (33)
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy (2008) (33)
Haemolytic uraemic syndrome during FK506 therapy (1992) (33)
A Case of Interstitial Pneumonia Induced by Rituximab Therapy (2005) (33)
Multiplex Real-time RT–PCR for Prospective Evaluation of WT1 and Fusion Gene Transcripts in Newly Diagnosed De Novo Acute Myeloid Leukemia (2004) (33)
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. (2010) (33)
B‐cell precursors differentiated from cord blood CD34+ cells are more immature than those derived from granulocyte colony‐stimulating factor‐mobilized peripheral blood CD34+ cells (2001) (32)
Missense mutations of the glycoprotein (GP) Ib beta gene impairing the GPIb alpha/beta disulfide linkage in a family with giant platelet disorder. (1997) (32)
Role of P‐glycoprotein in all‐trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA (2000) (32)
Characterization of the immunoglobulin heavy chain complementarity determining region (CDR)-III sequences from human B cell precursor acute lymphoblastic leukemia cells. (1992) (32)
BCR‐ABL‐independent and RAS / MAPK pathway‐dependent form of imatinib resistance in Ph‐positive acute lymphoblastic leukemia cell line with activation of EphB4 (2010) (32)
Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome (2005) (31)
Diagnosis of acute myeloid leukemia according to the WHO classification in the Japan Adult Leukemia Study Group AML-97 protocol (2008) (31)
PAX5–PML acts as a dual dominant-negative form of both PAX5 and PML (2011) (31)
Different T-cell receptor repertoires between lesions and peripheral blood in acute graft-versus-host disease after allogeneic bone marrow transplantation. (1996) (31)
Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group (2011) (31)
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia (2009) (30)
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study (2012) (30)
Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells (2016) (30)
SFK–STAT Pathway: An Alternative and Important Way to Malignancies (2006) (30)
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL (2018) (30)
Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms (2016) (30)
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study (2017) (29)
Allogeneic myeloablative transplantation for patients aged 50 years and over (2004) (29)
Genes for thrombopoietin and c‐mpl are not responsible for familial thrombocythaemia: a case study (1998) (29)
Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (2009) (29)
Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR–ABL-positive ALL (2012) (28)
Activation and destruction of platelets in patients with rheumatic heart disease. (1994) (28)
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (2009) (28)
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study (2009) (28)
Promoter Hypermethylation of the DNA-Repair Gene O6-Methylguanine—DNA Methyltransferase and p53 Mutation in Diffuse Large B-cell Lymphoma (2006) (28)
Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG). (1998) (27)
New enzyme-linked immunosorbent assay for glycocalicin in plasma. (1991) (27)
Disseminated intravascular coagulation in acute leukemia: clinical and laboratory features at presentation (2006) (27)
Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia (2018) (26)
Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study (2010) (26)
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity (2013) (26)
Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. (2006) (26)
Long‐term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia (2012) (26)
Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells (2015) (25)
Lack of Association between Intact/Deletion Polymorphisms of the APOBEC3B Gene and HIV-1 Risk (2014) (25)
Establishment of Mouse Model of MYH9 Disorders: Heterozygous R702C Mutation Provokes Macrothrombocytopenia with Leukocyte Inclusion Bodies, Renal Glomerulosclerosis and Hearing Disability (2013) (25)
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia (2014) (25)
FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. (2007) (24)
Y654 of β‐catenin is essential for FLT3/ITD‐related tyrosine phosphorylation and nuclear localization of β‐catenin (2012) (24)
Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells. (1997) (24)
Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. (1999) (24)
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system (2019) (24)
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes (2013) (24)
Cytogenetic characterization of a T-cell line, ATN-1, derived from adult T-cell leukemia cells. (1988) (24)
Prognostic analysis of aberrant somatic hypermutation of RhoH gene in diffuse large B cell lymphoma (2007) (23)
Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. (2000) (23)
LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22) (2007) (23)
SPIB is a novel prognostic factor in diffuse large B‐cell lymphoma that mediates apoptosis via the PI3K‐AKT pathway (2016) (23)
Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression Is a Favorable Prognostic Marker in Diffuse Large B-Cell Lymphoma (2006) (22)
PHASE III RANDOMIZED TRIAL OF VOLASERTIB PLUS LOW-DOSE CYTARABINE (LDAC) VERSUS PLACEBO PLUS LDAC IN PATIENTS AGED >= 65 YEARS WITH PREVIOUSLY UNTREATED AML, INELIGIBLE FOR INTENSIVE THERAPY (2016) (22)
Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD (2010) (22)
Prognostic implication and biological roles of RhoH in acute myeloid leukaemia (2008) (22)
Cord Blood Transplantation from Unrelated Donors: A Preliminary Report from the Japanese Cord Blood Bank Network (2003) (22)
Chrome congestive heart failure (1994) (22)
Molecular lesions in childhood and adult acute megakaryoblastic leukaemia (2012) (22)
Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis (2012) (22)
De novo mutation of the platelet glycoprotein Ib alpha gene in a patient with pseudo-von Willebrand disease. (1997) (22)
DETERMINATION OF FERRITIN AND HEMOSIDERIN IRON IN PATIENTS WITH NORMAL IRON STORES AND IRON OVERLOAD BY SERUM FERRITIN KINETICS (2012) (21)
Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome. (2012) (21)
Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy (2012) (21)
Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome (2003) (21)
Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype (2008) (21)
Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group (2008) (20)
Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation (2006) (20)
Induction of differentiation in acute promyelocytic leukemia cells by 9-cis retinoic acid alpha-tocopherol ester (9-cis tretinoin tocoferil). (1998) (20)
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. (2011) (20)
Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines. (2014) (20)
A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia (1998) (20)
Efficacy and safety of human adipose tissue-derived mesenchymal stem cells for supporting hematopoiesis (2012) (19)
Genomewide array‐based comparative genomic hybridization analysis of acute promyelocytic leukemia (2006) (19)
Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation. (2014) (19)
Irrespective of CD34 expression, lineage‐committed cell fraction reconstitutes and re‐establishes transformed Philadelphia chromosome‐positive leukemia in NOD / SCID / IL‐2Rγc−/− mice (2010) (19)
Vulnerable mutation Trp126 → stop of glycoprotein IX in Japanese Bernard – Soulier syndrome (1998) (19)
p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. (2009) (19)
[Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia]. (1999) (19)
The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib (2016) (19)
Skewed X chromosome inactivation in fraternal female twins results in moderately severe and mild haemophilia B (2008) (19)
Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma (2016) (19)
Significance of additional high-dose cytarabine in combination with cyclophosphamide plus total body irradiation regimen for allogeneic stem cell transplantation (2007) (19)
Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response (2018) (18)
Phenylarsine Oxide (PAO) More Intensely Induces Apoptosis in Acute Promyelocytic Leukemia and As2O3-Resistant APL Cell Lines than As2O3 by Activating the Mitochondrial Pathway (2004) (18)
[Classification of acute myeloid leukemia]. (2012) (18)
A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. (1998) (18)
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As2O3), but are not the main mechanism of As2O3-resistance in acute promyelocytic leukemia cells (2003) (18)
Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. (2012) (18)
CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. (2012) (18)
Mutation of ARHGAP9 in patients with coronary spastic angina (2010) (18)
Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study (2018) (17)
Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions (2016) (17)
Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood (2015) (17)
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study (2012) (17)
Characterization of the immunoglobulin light chain variable region gene expressed in multiple myeloma (1998) (17)
Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy (2021) (17)
Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy. (2022) (17)
Fatal thrombosis of antithrombin‐deficient mice is rescued differently in the heart and liver by intercrossing with low tissue factor mice (2006) (17)
Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates. (2007) (17)
Lyn Is an Important Component of the Signal Transduction Pathway Specific to FLT3/ITD and Can Be a Therapeutic Target in the Treatment of AML with FLT3/ITD. (2006) (17)
The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0 (2010) (17)
Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. (2013) (17)
Treatment With Hedgehog Inhibitor, PF-04449913, Attenuates Leukemia-Initiation Potential In Acute Myeloid Leukemia Cells (2013) (16)
Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM. (1991) (16)
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits (2015) (16)
Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders (2012) (16)
Short Communication Adipose Tissue-Derived Mesenchymal Stem Cells Facilitate Hematopoiesis in Vitro and in Vivo Advantages Over Bone Marrow-Derived Mesenchymal Stem Cells (2010) (16)
Impaired secretion of carboxyl-terminal truncated factor VII due to an F7 nonsense mutation associated with FVII deficiency. (2010) (16)
Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients (2006) (16)
An Sp1 binding site mutation of the PROS1 promoter in a patient with protein S deficiency (2007) (16)
The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line (2015) (16)
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group (2010) (16)
Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation (2006) (16)
Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study (2018) (16)
Expression cloning of oligomerization-activated genes with cell-proliferating potency by pseudotype retrovirus vector. (2004) (16)
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. (2021) (16)
Interaction of von Willebrand factor with the extracellular matrix and glycocalicin under static conditions. (1997) (15)
Molecular cloning and characterization of ZFF29: a protein containing a unique Cys2His2 zinc-finger motif. (2004) (15)
GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. (2013) (15)
A Randomized Trial Comparing Interferon-a! With Busulfan for Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (2002) (15)
Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study (2011) (15)
Development of hyperthyroidism in donor and recipient after allogeneic bone marrow transplantation. (1992) (15)
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: A retrospective analysis of JALSG‐APL97 (2013) (15)
Corrigendum: Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses (2016) (15)
Stable Engraftment after a Conditioning Regimen with Fludarabine and Melphalan for Bone Marrow Transplantation from an Unrelated Donor (2006) (15)
In vitro characterization of missense mutations associated with quantitative protein S deficiency (2006) (15)
Recurrent Intramural Hematoma of the Small Intestine in a Severe Hemophilia A Patient with a High Titer of Factor VIII Inhibitor: A Case Report and Review of the Literature (2006) (15)
Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency (2012) (15)
Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor. (2006) (14)
Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan (2008) (14)
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis (2011) (14)
KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo . (2007) (14)
A CASE OF CALL RELAPSE AFTER ALLOGENEIC BMT: RECURRENCE OF RECIPIENT CELL ORIGIN. INITIALLY DETERMINED AS BEING THAT OF DONOR CELL ORIGIN BY SEX CHROMOSOME ANALYSIS (1989) (14)
Mutations in the Nucleolar Phosphoprotein, Nucleophosmin, Promote the Expression of the Oncogenic Transcription Factor MEF/ELF4 in Leukemia Cells and Potentiates Transformation* (2013) (14)
Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review (2008) (14)
Spontaneous regression of aleukemic leukemia cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastosytosis (2009) (13)
Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene. (2006) (13)
Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. (1993) (13)
Phase II study of imatinib‐based chemotherapy for newly diagnosed BCR‐ABL‐positive acute lymphoblastic leukemia (2017) (13)
Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high‐dose chemotherapy and autologous stem cell transplantation (2009) (13)
Clinical protocol for angiogenesis by intramyocardial injection of autologous bone marrow mononuclear cells in patients with severe coronary artery disease: TACT-NAGOYA-HEART. (2006) (13)
FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling (2011) (13)
Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity (2018) (13)
Cytotoxic T-lymphocyte antigen 4 haplotype correlates with relapse and survival after allogeneic hematopoietic SCT (2011) (13)
Comparable gene structure of the immunoglobulin heavy chain variable region between multiple myeloma and normal bone marrow lymphocytes. (1996) (13)
Promising Outcome of Imatinib-Combined Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 Regimen. (2009) (13)
Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma. (2008) (13)
Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia (2018) (13)
T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. (2012) (13)
Molecular Heterogeneity of the PML Gene Rearrangement in Acute Promyelocytic Leukemia: Prevalence and Clinical Significance (1993) (13)
Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001–2005 using the Japan Adult Leukemia Study Group AML201 protocols (2018) (13)
The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies (2013) (12)
Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia. (2011) (12)
Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan (2008) (12)
B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia* (2015) (12)
Oncogenic protein tyrosine kinases (2004) (12)
A case of coagulation factor V deficiency caused by compound heterozygous mutations in the factor V gene (2006) (12)
Rapid detection of plasma glycocalicin by a latex agglutination test. A useful adjunct in the differential diagnosis of thrombocytopenia. (1993) (12)
CTL Clones Isolated from an HLA-Cw-Mismatched Bone Marrow Transplant Recipient with Acute Graft-Versus-Host Disease1 (2009) (12)
Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission (2016) (12)
Molecular analysis of the t(15;17) translocation in de novo and secondary acute promyelocytic leukemia. (1997) (12)
Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. (2007) (12)
The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells (2011) (12)
Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation (1999) (11)
Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis (2008) (11)
Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant (2012) (11)
Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212 (2020) (11)
Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor (2020) (11)
Management of infection in patients with acute leukemia during chemotherapy in Japan: questionnaire analysis by the Japan Adult Leukemia Study Group (2009) (11)
Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning (2019) (10)
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome (2014) (10)
Detection of unique neutrophil non‐muscle myosin heavy chain‐A localization by immunofluorescence analysis in MYH9 disorder presented with macrothrombocytopenia without leukocyte inclusions and deafness (2005) (10)
Comparable profiles of the immunoglobulin heavy chain complementarity determining region (CDR)-3 in CD5+ and CD5- human cord blood B lymphocytes. (1995) (10)
Unexpected heterogeneity of PML/RAR alpha fused mRNA detected by nested polymerase chain reaction in acute promyelocytic leukemia. (1993) (10)
[Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan]. (2005) (10)
Phase II study of dose‐modified busulfan by real‐time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy (2012) (10)
Successful second cord blood transplantation using fludarabine and cyclophosphamide as a preparative regimen for graft rejection following reduced-intensity cord blood transplantation (2007) (10)
Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia (2020) (10)
Molecular cloning of the breakpoint of t(11;22)(q23;q11) chromosome translocation in an adult acute myelomonocytic leukaemia (1996) (10)
Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia (2007) (10)
Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16. (1992) (10)
An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. (2017) (10)
Severe hemophilia A in a Japanese female caused by an F8-intron 22 inversion associated with skewed X chromosome inactivation (2010) (10)
Case-control study of leukemia and diagnostic radiation exposure. (1997) (10)
Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors. (2008) (10)
Excessively High-Affinity Single-Chain Fragment Variable Region in a Chimeric Antigen Receptor Can Counteract T-Cell Proliferation (2014) (10)
Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group (2017) (10)
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis (2015) (10)
Feasibility of salvage chemotherapy for refractory or relapsed non-Hodgkin's lymphoma with two topoisomerase II inhibitors, MST-16 and VP-16. MST-16 Study Group. (1996) (10)
Phase II study of intrabone single unit cord blood transplantation for hematological malignancies (2017) (10)
Diversity of Cellular Molecules in Human Cells Detected by Monoclonal Antibodies Reactive with c‐myc Proteins Produced in Escherichia coli (1989) (9)
Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group. (1999) (9)
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)‐AML206 study (2011) (9)
Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells. (2005) (9)
Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy. (2013) (9)
High Complete Remission Rate and Promising Outcome by Combination of Imatinib and Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia. (2005) (9)
Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. (2016) (9)
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy (2015) (9)
PAX5-PML Acts as a Dual Dominant-Negative Form of Both PAX5 and PML. (2009) (9)
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan (2010) (9)
Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse (2015) (9)
Successful Treatment with Imatinib Mesylate of a CML Patient in Megakaryoblastic Crisis with Severe Fibrosis (2002) (9)
A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH gene. (2003) (9)
Outcome of Pediatric-Type Therapy for Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA): A Study by the Japan Adult Leukemia Study Group (JALSG ALL202-U study) (2012) (8)
Increased but highly dispersed levels of plasma glycocalicin in patients with disseminated intravascular coagulation (1996) (8)
A novel RUNX1-C11orf41 fusion gene in a case of acute myeloid leukemia with a t(11;21)(p14;q22). (2012) (8)
Involvement of the MLL/ALL-1 gene associated with multiple point mutations of the N-ras gene in acute myeloid leukemia with t(11;17)(q23;q25) (1993) (8)
Genetic Predispositions to Myeloid Neoplasms Caused By Germline DDX41 Mutations (2015) (8)
Correction: Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults (2016) (8)
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice (2013) (8)
Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR–ABL inhibitors (2012) (8)
Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201 (2017) (8)
Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation (2006) (8)
A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. (2011) (8)
Potent antiproliferative effect of fatty‐acid derivative AIC‐47 on leukemic mice harboring BCR‐ABL mutation (2019) (7)
Establishment of a Stroma-Dependent Human Acute Myelomonocytic Leukemia Cell Line, NAMO-2, with FLT3 Tandem Duplication (2006) (7)
L1503R is a member of group I mutation and has dominant‐negative effect on secretion of full‐length VWF multimers: an analysis of two patients with type 2A von Willebrand disease (2008) (7)
Biological and clinical significance of the FLT 3 transcript level in acute myeloid leukemia (2003) (7)
Definite diagnosis in Japanese patients with protein C deficiency by identification of causative PROC mutations (2009) (7)
Potential role of a mismatched HLA-specific CTL clone developed pre-transplant in graft rejection following cord blood transplantation. (2008) (7)
A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia. (2016) (7)
Immunoaffinity purification and characterization of CACGTG sequence-binding proteins from cultured mammalian cells using an anti c-Myc monoclonal antibody recognizing the DNA-binding domain. (1997) (7)
Disappearance of minimal residual lymphoblastic leukemia cells 6 months after allogeneic bone marrow transplantation without GVHD. (1991) (7)
Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection (2015) (7)
Dasatinib-based 2-step induction for adults with Philadelphia chromosome–positive acute lymphoblastic leukemia (2021) (7)
Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia (2019) (7)
A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy. (2017) (7)
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study (2012) (7)
Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography (2018) (7)
Immunoglobulin variable region structure and B-Cell malignancies (2001) (7)
INCREASING AND DECREASING PHASES OF FERRITIN AND HEMOSIDERIN IRON DETERMINED BY SERUM FERRITIN KINETICS (2013) (7)
Monoclonal antibodies reactive to human platelets: analysis of their specificities, detected antigen molecules, and their effects on platelet function. (1987) (6)
Preliminary Results from a Phase 1/2 Study of DSP-7888, a Novel WT1 Peptide-Based Vaccine, in Patients with Myelodysplastic Syndrome (MDS) (2016) (6)
Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study (2013) (6)
High incidence of secondary failure of platelet recovery after autologous and syngeneic peripheral blood stem cell transplantation in acute promyelocytic leukemia (2007) (6)
Autoantibodies to c-myc nuclear protein products in autoimmune disease. (1990) (6)
Delayed or insufficient restoration of PML and PML-RAR alpha subcellular localization after exposure in vitro to retinoic acids in all-trans retinoic acid-resistant APL cells. (1995) (6)
163. Remission induction therapy of refractory acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) (1992) (6)
RHOF PROMOTES MURINE MARGINAL ZONE B CELL DEVELOPMENT (2014) (6)
Long-Term Follow-up of the Randomized JALSG AML 201 Study Comparing High Dose Ara-C Therapy with Conventional Consolidation Therapy in Adult Acute Myeloid Leukemia (AML) (2008) (6)
Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms (2012) (6)
Bone marrow transplantation in 614 patients: twenty year experience of the Nagoya Bone Marrow Transplantation Group (NBMTG). (1995) (6)
Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment (2010) (6)
Efficacy and resistance of molecularly targeted therapy for myeloid malignancies Mechanisms of action and resistance to all-trans retinoic acid ( ATRA ) and arsenic trioxide ( As 2 O 3 ) in acute promyelocytic leukemia (2013) (6)
High Titer of ADAMTS13 Inhibitor Associated with Thrombotic Microangiopathy of the Gut and Skeletal Muscle after Allogeneic Hematopoietic Stem Cell Transplantation (2006) (6)
Mutational analysis of SOS1 gene in acute myeloid leukemia (2008) (6)
Clinical Characteristics and Outcomes in Patients with t(8;21) Acute Myeloid Leukemia in Japan. (2007) (6)
Sphingosine kinase 1 expression is downregulated during differentiation of Friend cells due to decreased c-MYB. (2013) (6)
Successful umbilical cord blood transplantation using a reduced-intensity preparative regimen without total body irradiation and tacrolimus plus methotrexate for prophylaxis of graft-versus-host disease in a patient with adult T-cell leukemia/lymphoma (2007) (5)
Relationship Between Degradation of PML-RAR and Differentiation (1999) (5)
A human monoclonal antibody that detects HLA-A1, A23 and A24 antigens. (1993) (5)
Continuing immunoglobulin heavy chain gene rearrangements in chronic myeloid leukemia with recurrent B-lymphoid blast crises after bone marrow transplantation. (1995) (5)
Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults (2008) (5)
[Thrombotic thrombocytopenic purpura with mixed connective tissue disease. A case report]. (2009) (5)
Virus-associated hemophagocytic syndrome caused by pandemic swine-origin influenza A (H1N1) in a patient after unrelated bone marrow transplantation. (2011) (5)
In vivo tracking of transplanted macrophages with near infrared fluorescent dye reveals temporal distribution and specific homing in the liver that can be perturbed by clodronate liposomes (2020) (5)
[Differentiation therapy of acute promyelocytic leukemia with all-trans retinoic acid]. (1993) (5)
The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis (2013) (5)
Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. (2013) (5)
Abstract 1884: Treatment with Hedgehog inhibitor PF-913 attenuates leukemia-initiation potential in acute myeloid leukemia cells (2014) (5)
Production and analysis of HH 10 monoclonal antibodies reactive to immature hematopoietic cells and their use for monitoring acute leukemia cells. (1985) (5)
Randomized controlled trials of treatments for hematologic malignancies (2007) (5)
Phase II Trial of a Peptide Vaccine, Ocv-501 in Elderly Patients with Acute Myeloid Leukemia (2018) (5)
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial (2021) (5)
Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes (2008) (5)
Imatinib-Based Chemotherapy for Newly Diagnosed BCR–ABL Positive Acute Lymphoblastic Leukemia: Japan Adult Leukemia Study Group (JALSG) Ph+ALL208 Study (2014) (4)
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale (2016) (4)
Comparison of the immunoglobulin heavy‐chain complementarity determining region‐3 structure among the DNA sequences and the μ‐ and γ‐transcripts in human B‐lineage cells (1996) (4)
A Phase III Study of New Synthetic Retinoid Tamibarotene(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study (2012) (4)
Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein (2018) (4)
[Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia]. (2010) (4)
MicroRNA Functions as a Potential Growth Suppressor in Human Colon Cancer Cells (2006) (4)
Report on the use of non‐clinical studies in the regulatory evaluation of oncology drugs (2016) (4)
Efficacy of Gemtuzumab Ozogamicin (GO) Monotherapy on Relapsed/Refractory Acute Promyelocytic Leukemia (APL) (2011) (4)
A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia. The Kouseisho Leukemia Study Group. (1998) (4)
Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia (2010) (4)
Tamibarotene for the treatment of acute promyelocytic leukemia (2014) (4)
Acute Myeloid Leukemia in the Elderly: - 159 Nagoya Case Studies- (1999) (4)
ZNF384‐fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities (2019) (4)
Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia. (2018) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
Minimal residual disease status in pre-B acute lymphoblastic leukemia patients after chemotherapy and bone marrow transplantation: assessment of the anti-leukemic effects of chemotherapy and BMT. (1993) (4)
Chemical speciation of arsenic species in human blood serum by liquid chromatography using a phosphatidylcholine-coated ODS column with detection by ICP-MS (2007) (4)
BCR–ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells (2016) (4)
Nucleotide sequences of the variable regions of a human monoclonal antibody against HLA-A1, A23, and A24. (1993) (4)
FL-Dependent Wild-Type FLT3 Signals Reduce the Inhibitory Effects of FLT3 Inhibitors On Wild-Type and Mutant FLT3 Co-Expressing Cells. (2009) (4)
Around 70% of Japanese CML Patients Could Stop Imatinib According to a-STIM Criteria: The JALSG-STIM213 Study (2015) (4)
PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation. (2016) (4)
Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy (2005) (4)
[Pathogenesis of acute myeloid leukemia]. (2012) (4)
Anti-CD20 Chimeric Antigen Receptor Transduced T Cells Can Recognize Very Low Antigen Expression: Determination Of The Lower Threshold Required To Activate The CAR-T Cells (2013) (3)
Treatment of myelodysplastic syndromes with orally administered N-(2S, 3R)-3-amino-2-hydroxy-4-phenylbutyryl-L-leucine (ubenimex). (1991) (3)
Correlation of Serum IL-6 Level with Exhaustion of Cytomegalovirus-specific T Cells After Hematopoietic Stem Cell Transplantation (2011) (3)
EPSTEIN–BARR VIRUS (EBV)-ASSOCIATED T/NK LYMPHOPROLIFERATIVE DISEASES IN NON-IMMUNOCOMPROMISED HOSTS: PROSPECTIVE ANALYSIS OF 108 CASES (2011) (3)
Comparison of the immunoglobulin gene transcripts between immature B lineage acute lymphoblastic leukemia and the normal phenotypic counterparts in the bone marrow (1997) (3)
A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS) (2015) (3)
Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody (2015) (3)
Exhaustion of CMV Specific T Cells with Enhanced PD-1 Expression In Persistent Cytomegalovirus Infection After Allogeneic Stem Cell Transplantation (2010) (3)
Developing target therapy against oncogenic tyrosine kinase in myeloid maliganacies. (2006) (3)
Combination of Intensive Chemotherapy and Imatinib (IDEAMOP Regimen) for the Treatment of Newly Diagnosed BCR-ABL Positive Acute Lymphoblastic Leukemia; Excellent Efficacy without Increasing Toxicity. (2004) (3)
Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse. (1995) (3)
[Efficacy of early administration of G-CSF after intensive chemotherapy in acute leukemia: a randomized controlled trial. Tokai Infection Study Group on Hematological Disorders]. (1995) (3)
Mechanism of FLT3 ligand dependent resistance to FLT3 inhibitors (2014) (3)
Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent or T315I-Mutated Cells. (2009) (3)
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia (2021) (3)
Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line (2020) (3)
Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature (2020) (3)
Genomic and Clinical Characterization of Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia (2018) (3)
A Novel STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition in a Wide Range of Hematopoietic Malignancies without Growth Suppression of Normal Hematopoietic Cells (2011) (3)
Role of Hematopoietic Stem Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated with All-Trans-Retinoic Acid: A Retrospective Analysis of the Japan Adult Leukemia Study Group (JALSG) APL97 Study (2011) (3)
[A "retinoic acid syndrome" observed in two cases of acute promyelocytic leukemia]. (1993) (3)
Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia. (1999) (3)
Double Genetic Mutations in PML-Rara Fusion Gene Confirmed in a Patient Showing Resistance to All-Trans Retinoic Acid and Arsenic-Trioxide Therapy. (2009) (3)
Randomized Clinical Trial of Induction Therapy Comparing Intensified Daunorubicin with Idarubicin in Patients with Previously Untreated De Novo Acute Myeloid Leukemia (JALSG AML201 Study). (2006) (3)
Chimeric antisense RNA derived from chromosomal translocation modulates target gene expression (2012) (3)
Effect of treatment with hedgehog inhibitor, PF-04449913, on leukemia-initiation potential in acute myeloid leukemia cells. (2013) (3)
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation. (2019) (3)
Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations (2015) (3)
[Therapy-related leukemia]. (2003) (3)
[Prognostic factors related to remission duration and the effects of maintenance therapy in BHAC-DMP therapy in adult acute non-lymphocytic leukemia patients]. (1986) (2)
R702C Mutation of the MYH9 Gene Provokes Impaired Platelet Formation, Renal Focal Segmental Glomerulosclerosis, and Hearing Disability In the Mice Model (2010) (2)
Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria (2011) (2)
Erratum: CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77) (2009) (2)
DNMT3A and IDH1/2 Mutations Are Stable During the Progression of Acute Myeloid Leukemia (2011) (2)
Clinicopathological Manifestations and Treatment of Intestinal Transplant-Associated Microangiopathy (i-TAM) (2009) (2)
KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo. (2008) (2)
Mechanism-based therapy for leukemia: a lesson from ATRA therapy. (2001) (2)
Quality of life in adult patients after bone marrow transplantation (1998) (2)
Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology. (2007) (2)
A single minor histocompatibility antigen AELLNIPFLY encoded by UGT2B17 is presented by HLA-A2902, B4402 and B4403 (2006) (2)
Leukemia Relapse Reconsidered from the Molecular Aspect (2000) (2)
Acetylation of PML Plays a Key Role in Histone Deacetylase Inhibitor-Mediated Apoptosis through Enhanced PML Sumoylation. (2007) (2)
Phase 1/2 study evaluating the safety and efficacy of DSP‐7888 dosing emulsion in myelodysplastic syndromes (2021) (2)
Postremission Therapy in Adult Acute Myeloid Leukemia (AML): A Randomized Comparison between High Dose Ara-C Therapy and Conventional Consolidation Therapy (JALSG AML 201 Study). (2006) (2)
Production of a truncated human c‐myc protein which binds to DNA (1988) (2)
[Intravascular large B-cell lymphoma; recent advances and future perspectives]. (2010) (2)
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation during First Complete Remission Following Imatinib-Combined Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (2008) (2)
Development of acute pure red cell aplasia after deferasirox administration in two cases of myelodysplastic syndrome. (2014) (2)
Karyotypically independent clones with del(11q) and trisomy 10 in acute myeloid leukemia: trisomy 10 may appear as an additional change (2008) (2)
Escape of leukemia blasts from HLA-specific CTL pressure in a recipient of HLA one locus-mismatched bone marrow transplantation. (2012) (2)
Prospective Comparison of Azacitidine Treatment between 7-Days and 5-Days Schedules for Patients with Higher-Risk Myelodysplastic Syndromes; Results of Japan Adult Leukemia Study Group MDS212 Trial (2019) (2)
Retention but Significant Reduction of BCR-ABL Transcript in Hematopoietic Stem Cells in Chronic Myelogenous Leukemia after Imatinib Therapy. (2008) (2)
Molecular Characteristics That Predict Response to Azacitidine Therapy (2019) (1)
[Use of cyclosporin A in 5 leukemia patients receiving allogeneic bone marrow transplantation]. (1984) (1)
Eosinophils Derived from Acute Promyelocytic Leukemia Cells after Arsenic Trioxide Treatment (2007) (1)
Production of chimeric protein coded by the fused viral H-ras and human N-ras genes in Escherichia coli. (1987) (1)
Microvesicles released from hormone-refractory prostate cancer cells facilitate mouse pre-osteoblast differentiation (2012) (1)
[Simultaneous analysis of c-myc protein expression and cell cycle with monoclonal antibody and flow cytometry]. (1992) (1)
Clinical Features and Outcomes of Elderly Patients with Acute Promyelocytic Leukemia (APL) - the Japan Adult Leukemia Study Group APL97 Study. (2010) (1)
Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells (2010) (1)
Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial (2022) (1)
Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial (2021) (1)
Characterization of Cytotoxic T Lymphocyte Clones Isolated from Bone Marrow Transplant Recipient with HLA-Cw-Mismatched Donor (2008) (1)
Factors Associated with Relapse-Free Survival in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Imatinib-Combined Chemotherapy. (2007) (1)
A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia (2022) (1)
Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200 (2018) (1)
Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells. (2010) (1)
Variable region gene analysis of 2 human monoclonal-antibodies to gd3. (1993) (1)
[Genetic diagnosis of chronic myeloid leukemia]. (2001) (1)
Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study (2014) (1)
Treatment of myelodysplastic syndrome with all-trans retinoic acid (1993) (1)
Clinical Significance of Genetic Mutations of CD79B, CARD11, MYD88, and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients (2011) (1)
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (2009) (1)
345: Decreased Risk of Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with the 5,10-Methylenetetrahydrofolate Reductase 677TT Genotype (2008) (1)
Molecular Signatures That Predict Response to Azacitidine Treatment for Myelodysplastic Syndromes (2017) (1)
Unusual feature of the T-cell receptor genes in T-lineage acute lymphoblastic leukemia. (1997) (1)
Successful unrelated cord blood transplantation for adult acquired aplastic anemia using reduced intensity conditioning without ATG. (2014) (1)
[Human monoclonal antibodies with human-mouse hybridomas]. (1983) (1)
Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. (2023) (1)
Production of monoclonal antibodies reactive with c-myc protein and analysis of the c-myc expression in leukemic cells. (1988) (1)
FLT3/ITD Regulates Leukemia Cell Adhesion through α4β1 Integrin and Pyk2 Signaling. (2009) (1)
Cell Surface Antigens on Human Leucocytes Defined by Murine Monoclonal Antibodies (1984) (1)
A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling (2010) (1)
Combination of the Histone Deacetylase Inhibitor Vorinostat with a B-Cell Receptor Signaling Inhibitor Markedly Decreases Cyclin D1 Expression in a Mantle Cell Lymphoma Cell Line (2014) (1)
Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study (2018) (1)
Prognostic Analysis of Aberrant Somatic Hypermutation of RhoH in Diffuse Large B Cell Lymphoma. (2006) (1)
Relationship between degradation of PML-RARalpha and differentiation. (1999) (1)
A Double-blind Controlled Study of G-CSF Started Two Days Before Induction Chemotherapy in Refractory Acute Myeloid Leukemia (1996) (1)
Updated Results of JALSG AML201 Study Comparing Intensified Daunorubicin with Idarubicin in Patients with De Novo Acute Myeloid Leukemia: Effect of Hematopoietic Stem Cell Transplantation. (2008) (1)
Impact of Homozygous Deletion of UGT2B17 on Outcome of Allogeneic BMT. (2004) (1)
＜Editors’ Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement (2020) (1)
[A comparative clinical study on flucytosine alone and in combination with fluconazole in hematological malignancies: a multicenter study using the envelope method]. (1994) (1)
The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line (2015) (1)
Evaluation of clinical performance of the major BCR-ABL mRNA detection kit which enables conversion to international standard scale using the reference material calibrator. (2014) (1)
Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms (2013) (1)
Classic Polyarteritis Nodosa Presenting Rare Clinical Manifestations in a Patient with Hemophilia A (2006) (1)
Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment (2008) (1)
Epigenetic Regulation of CD20 Protein Expression in B-Cell Lymphoma Cells after Rituximab-Containing Chemotherapy. (2007) (1)
Allogeneic HSCT at the first remission for younger adults with FLT3-ITD AML: The JALSG AML209-FLT3-SCT Study. (2020) (1)
Clinical Features and Prognosis of Unselected Patients with AML and RAEB-2: Japan Adult Leukemia Study Group CS-07 Study (2016) (1)
Atlas of blood disease on the internet. (1996) (1)
Iron chelation therapy for a case of transfusion-independent MDS-RARS with significant iron overload (2012) (1)
Transcriptional Activity of MEF/ELF4 on the HDM2 Promoter Is Enhanced by the Mutation of the NPM1 Gene (2010) (1)
A Novel Direct STAT3 Inhibitor OPB-31121 Induces Tumor-Specific Growth Inhibition In a Wide Range of Hematopoietic Malignancies and Effectively Suppresses the Chemotherapy Resistant Quiescent Cells In Vivo (2010) (1)
Long-Term Outcome Of Acute Promyelocytic Leukemia (APL) With Lower Initial Leukocyte Counts By Using All-Trans Retinoic Acid (ATRA) Alone For Remission Induction Therapy: Japan Adult Leukemia Study Group (JALSG) APL97 Study (2013) (1)
Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study (2020) (1)
Phase 2 Study of FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report From the Japan Adult Leukemia Study Group (JALSG). (2009) (1)
CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients (2013) (1)
Analysis of the Role of Wnt Signaling for the Interaction between Leukemia Cells and Stroma. (2007) (0)
Clinical Features and Prognostic Impact of CD56 Expression in Acute Promyelocytic Leukemia: Long Term Follow up Data From the Japan Adult Leukemia Study Group(JALSG) APL97, (2011) (0)
Biomarker and Gene Profiling Analyses in Acute Myeloid Leukemia during Treatment with Hedgehog Signaling Inhibitor (2015) (0)
A Randomized Trial Comparing Individualized Vs. Non-Individualized Treatment for Elderly Acute Myeloid Leukemia: JALSG GML200 Study (2008) (0)
[Circumventing resistance to imatinib therapy in chronic myeloid leukemia]. (2009) (0)
[Clinical trial of bestrabucil (KM 2210) in hematopoietic malignancies]. (1986) (0)
O1-19-4Biomarker and gene profiling analyses in acute myeloid leukemia during treatment with Hedgehog signaling inhibitor (2015) (0)
Integrated Molecular Analysis of Myelodysplastic Syndromes Using Whole Genome Sequencing (2016) (0)
Review of the immunoglobulin light chain variable region sequences from multiple myeloma cells (1999) (0)
Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS. (2020) (0)
Correction to: Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning (2019) (0)
P3–137EFFICACY AND BIOMARKER ANALYSES OF TREATMENT WITH THE HEDGEHOG INHIBITOR, PF-04449913, IN AML CELLS (2013) (0)
[Oncogenes and its products in hematopoietic malignancies]. (1987) (0)
[Clinical study of high-dose chemotherapy with peripheral blood stem cell transplantation for poor-risk germ cell tumor]. (1999) (0)
Phase 2 study of FLAGM (Fludarabine+high-dose ara-C+G-CSF+Mitoxantrone) for refractory or relapse acute myeloid leukemia (AML): a report from the Japan Adult Leukemia Study Group (JALSG) (2010) (0)
Novel Mechanism of Activated FLT3-Associated Leukemogenisis: FLT3 Regulates Wnt Signaling by Phosphorylating β-Catenin and Promoting β-Catenin Nuclear Localization. (2005) (0)
Biomarker assay for residual chronic myeloid leukemia stem/progenitor cells during treatment with ABL-tyrosine kinase inhibitors (2012) (0)
Prognostic Impact of Chromosomal Variation in Patients with Acute Promyelocytic Leukemia (APL); Analysis of 775 Cases Enrolled in the Japan Adult Leukemia Study Group APL Studies (2014) (0)
[FLT3 tyrosine kinase inhibitors: current status and future perspectives for their development]. (2008) (0)
P-23 Immunohistochemistry of P53 and HBF and chromosome analysis are useful for differentiating MDS(RA) from aplastic anemia (2005) (0)
[A case of posthepatitic severe aplastic anemia treated with allogeneic bone marrow transplantation (author's transl)]. (1979) (0)
Rapid Detection of Plasma Glycocalicinby a Latex Agglutination Test and Its Use in the Differential Diagnosis of Thrombocytopaenia (1997) (0)
Guest editorial: Introducing progress in hematology in this issue (2012) (0)
[Molecule targeted therapy for hematological malignancies]. (2001) (0)
Odk-1201, One-Step RT-qPCR Major BCR-ABL/ABL mRNA Kit for the International Scale, with High Sensitivity to Detect Deeper MR (2014) (0)
Efficacy and Safety of Tyrosine Kinase Inhibitors for Treatment of Newly Diagnosed Chronic Myeloid Leukemia: Results Using Data Obtained with the New Target System from the Japanese Registry (2018) (0)
Homing, Proliferating and Surviving Sites of Human Leukemia Cells In Vivo in Immunodeficient Mice. (2006) (0)
BMI-1 Overexpression in 32Dcl3 Cells Suppresses Granulocytic Differentiation and Ameliorates Their Growth under IL-3 Diminished Conditions. (2005) (0)
Development and Analysis of Novel Intravascular Large B-Cell Lymphoma NOD/Shi-Scid IL2Rγnull Mouse Xenograft Model (2014) (0)
Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study (2018) (0)
Triphasic Exponential Decline of BCR-ABL Transcripts during Imatinib Therapy for Chronic Myelogenous Leukemia. (2005) (0)
[Chromosome abnormalities and their clinical significance in leukemia and lymphoma]. (1999) (0)
CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma (2010) (0)
PAX5 Phosphorylation by MAP Kinase Signal Potentially Suppresses PAX5 Function and Might Be a Trigger of the Plasma Cell Differentiation (2010) (0)
Treatment with Hsp90 Inhibitor, 17-AAG Overcomes Resistance to Small Molecule FLT3-Inhibitors in FLT3/ITD-Positive Leukemia Cells Harboring N676K-Mutation. (2008) (0)
ACUTE MYELOID LEUKEMIA IN THE ELDERLY :-159 NAGOYA (2011) (0)
Establishment of a NOD/SCID/γc−/−-Dependent Lymphoid Leukemia Cell Line, D593, with Novel RUNX1-LAF4 Fusion Gene. (2006) (0)
A Photosensitizer Verteporfin Has Light-Independent Anti-Leukemic Activity for Ph-Positive Acute Lymphoblastic Leukemia and Synergistically Works with Dasatinib in Vivo (2015) (0)
Restoration of Rituximab Sensitivity in CD20 Negative B-Cell Lymphoma Cells; Epigenetic Change of CD20 Expression after Treatment of Rituximab. (2006) (0)
8. Molecular Pathogenesis and New Treatment of Myelodysplastic Syndrome (2009) (0)
Clinical Impact of Underweight on the Outcome of Patients with Acute Myeloid Leukemia: Retrospective Study of JALSG AML201 (2016) (0)
[Is allogeneic bone marrow transplantation the first choice for acute leukemia in first remission? From chemotherapeutical point of view]. (1991) (0)
成人急性骨髄性白血病(AML)における末梢血液のWTI遺伝子mRNA検出の予後影響 (2005) (0)
[109th Scientific Meeting of the Japanese Society of Internal Medicine: invited lecture: 5. Molecular target therapy for leukemia]. (2012) (0)
[Standard chemotherapy of hematological cancers]. (2009) (0)
ZNF384-Fusion Proteins Have High Affinity to EP300, Which Increases Their Transcriptional Activities (2018) (0)
[New approaches of differentiation-inducing therapy for leukemia]. (1999) (0)
CD56 Is an Unfavorable Prognostic Factor for Acute Promyelocytic Leukemia: Results By Multivariate Analyses in the JALSG-APL204 Study (2018) (0)
Southern blot analysis of Bcr, N-ras, H-ras, c-myc and myb proto-oncogenes in blast crisis of chronic myelogenous leukemia. (1989) (0)
Serological and biochemical characterization of surface antigen expressed on human myeloid cells and identification of six distinct antigen systems. (1988) (0)
Title Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study (2017) (0)
[A case of "microgranular" acute promyelocytic leukemia: the first case report in Japan (author's transl)]. (1981) (0)
Cell Differentiation Mechanism of Antigen-Triggering Plasma through PAX5 Phosphorylation: A PAX5-Dependent Repression of BLIMP1 B Cell Receptor-ERK1/2 Signal Cancels (2012) (0)
[Detection of minimal residual leukemia using polymerase chain reaction method]. (1996) (0)
Drug Development Targeting Microenvironment for Malignant Lymphoma (2012) (0)
Prognostic Impact of the Detection of the WT1 Gene mRNA with Peripheral Blood in Adult Acute Myeloid Leukemia (AML). (2005) (0)
[Acute leukemia]. (2007) (0)
RhoH Downregulates Rac Through RhoGAP Family Protein (2011) (0)
Clinical significance of 18F-alpha-methyl tyrosine PET as a potential surrogate marker of LAT1 expression for predicting prognosis of non-small cell lung cancer. (2010) (0)
[Leukemia specific chimeric protein as a target molecule for chemotherapy]. (1998) (0)
[Three cases of ABO incompatible allogeneic bone marrow transplantation]. (1982) (0)
1018. Prevalence of Bacteremia/Fungemia and Pneumonia in Remission Induction Chemotherapy for Adult Acute Myeloid Leukemia From 1987 to 2005: Japan Adult Leukemia Study Group (JALSG) (2018) (0)
αvβ3 Integrin Activation and Matrix Binding Mediate Cellular Responses to Mechanical Stretch. (2005) (0)
Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults. (2005) (0)
Outcomes Of Allogeneic Hematopoietic Stem Cell Transplantation In AML Patients Registered In Prospective Studies: The JALSG Experience (2013) (0)
Pirarubicin (THP) therapy for elderly aggressive non-Hodgkin's lymphoma- T-COP vs reduced CHOP, and reduced T-COP in the patients with poor physical status. (2006) (0)
Histone Deacetylase 3 (HDAC3), a Component of N-CoR-TBL1/R1 Chromatin Remodeling Co-Repressor Complex, Is Recruited to the Target Gene Promoters by PML-RARα To Repress the Transcription In Vivo . (2005) (0)
Clinical Significance of Wt1 mRNA Levels in Japanese Acute Lymphoblastic Leukemia Patients (2017) (0)
5. Molecular Target Therapy for Leukemia (2012) (0)
A Phase I/II Trial of Gemtuzumab Ozogamicin in Combination with Cytarabine and Anthracyclines (Daunorubicin or Idarubicin) for CD33-Positive Refractory or Relapsed AML Patients Younger Than 65 Years. Results of Phase I Parts of the JALSG-AML206 Study. (2009) (0)
Detection of BCR-ABL Transcript by Quantitative Real-Time PCR and Amp-CML (Transcript Mediated Amplification) during Imatinib Therapy for Chronic Myeloid Leukemia. (2006) (0)
Title Report on the use of non-clinical studies in the regulatoryevaluation of oncology drugs (2019) (0)
Deregulated Activity of AML1/RUNX1 Cooperates with BCR-ABL to Immortalize Hematopoietic Progenitor Cells and Induces Blast Crisis-Like Disease of Chronic Myelogenous Leukemia in Mice, (2011) (0)
Cancer Therapy : Preclinical See related commentary by Dao and Tyner , p . 1309 Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL 1 – Positive Leukemia (2013) (0)
Expression of CD56 Is an Independent Prognostic Factor to Predict Relapse in Acute Myeloid Leukemia with t(8;21): Results of Japan Adult Leukemia Study Group (JALSG) AML97 Protocol. (2012) (0)
Quantification of MRD in rituximab plus CHOP (R-CHOP) therapy in follicular lymphoma (FL): Results of a randomized trial comparing the concurrent and sequential administrations. (2004) (0)
Chronic Graft-Versus-Host Disease after Allogenaic Bone Marrow Transplantation in Japan: Identification of Risk Factors and Prognostication. (2005) (0)
A new approach of anti-leukemic therapy by histone deacetylase inhibitors. (1998) (0)
Preface (2006) (0)
[New strategy for diagnosis and treatment of acute promyelocytic leukemia with t (15;17)]. (1994) (0)
Anti–leukemia Activity of a Novel KIT Selective Inhibitor KI–328. (2009) (0)
T 315 I Mutation in Ph-positive Acute Lymphoblastic Leukemia is Associated with a Highly Aggressive Disease Phenotype : Three Case Reports (2012) (0)
Comprar Integrated Molecular Medicine for Neuronal and Neoplastic Disorders | Gen Sobue | 9781573316552 | Blackwell Publishing (2007) (0)
[The 40th scientific meeting: perspectives of internal medicine; present situation and future extension of organ transplantation in Japan; 8. Hematopoietic stem cell transplantation]. (2013) (0)
Residual Blast Cells in Bone Marrow on Day 15 Following Remission Induction Therapy for Acute Myeloid Leukemia Is Associated with Long-Term Prognosis: A Retrospective Analysis of the JALSG AML201 Study (2016) (0)
[A case of chronic myelocytic leukemia in blast crisis treated with allogeneic bone marrow transplantation]. (1982) (0)
Modified Effector CD8 - Antigen Receptor Chimeric ζ CD20-CD28-CD3 - of AntiAntigen Density Governs the Efficacy (2014) (0)
O1-1-3TREATMENT WITH HEDGEHOG INHIBITOR, PF-913, ATTENUATES LEUKEMIA-INITIATION POTENTIAL IN AML CELLS (2014) (0)
Cord Blood Allograft Rejection Mediated By Coordinated Donor-Specific Cellular and Humoral Immune Processes (2013) (0)
Brief history of the Asiatic International Society of Hematology: our roots of international cooperation with Asian countries (2018) (0)
Detecting K cell Subpopuration in Patients with Various Diseases by the Microplate Method (1981) (0)
PAX5-PML Acts as a Dual Dominant-Negative Form of PAX5 and PML (2010) (0)
Issue Information (2021) (0)
RCT of CPFX and CFPM (2013) (0)
Wnt Signaling Is Associated with Anti-Apoptosis in the Interaction Between Acute Myeloid Leukemia Cells and Stromal Cells (2012) (0)
[Recent progress in therapy for hematological malignancies]. (2006) (0)
[A case of post-hepatitic severe aplastic anemia treated with allogeneic bone marrow transplantation]. (1984) (0)
Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1 (2019) (0)
[Allogeneic bone marrow transplantation in 14 cases of leukemia]. (1982) (0)
Landscape of DNA Methylation and Genetic Profiles in 291 Patients with Myelodysplastic Syndromes (2015) (0)
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia Improved Long Term Relapse-Free Survival: 7-Year Results from a Randomized Controlled Trial, JALSG-APL204 (2017) (0)
T2013 Deregulated Expression of MicroRNA-143, -145, -7, -21 and -34a in Colon Tumor Development (2009) (0)
Assessment of the International Prognostic Scoring System for Determining Chemotherapeutic Indications in Myelodysplastic Syndrome: Japanese Retrospective Multicenter Study (2005) (0)
Nagoya University Ethics Committee^|^#39;s Preliminary Review Process: A Descriptive Study (2013) (0)
Clathrin Assembly Protein CALM Is Necessary for Leukemia Cell Proliferation and Erythroid Development Via Regulating Transferrin Receptor Endocytosis (2011) (0)
[ACNP therapy for DCMP-resistant acute leukemia (author's transl)]. (1981) (0)
Intrabone Transplantation of a Single Cord Blood Unit Using Non-Irradiated Reduced-Intensity Conditioning (2016) (0)
Effect Of Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Haplotype On Allogeneic Hematopoietic Stem Cell Transplantation (2010) (0)
Plasma immunoadsorption combined with exchange for removal of isohemagglutinin in major ABO-incompatible bone marrow transplantation: a case report. (1987) (0)
PAX5-PML Induces Pro B Acute Lymphoblastic Leukemia in Mice (2014) (0)
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia (2017) (0)
Genetic Landscape and Clonal Evolution Following 5-Aza Therapy in Patients with High-Risk Myelodysplastic Syndromes (2016) (0)
Clinical and cost benefit of aprepitant in patients receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation. (2014) (0)
Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography (2018) (0)
WT-1 Expression Level In BM Is The Great Prognostic Marker In Three Of Classification IPSS, WPSS, and Latest Revised IPSS(IPSS-R) (2013) (0)
Issue Information (2020) (0)
Quantification of MRD in rituximab plus CHOP (R-CHOP) therapy in follicular lymphoma (FL): Results of a randomized trial comparing the concurrent and sequential administrations (2004) (0)
Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities (2019) (0)
Serum α1-Acid Glycoprotein Level Associate with Imatinib Trough Plasma Concentration and Clinical Outcome in CML Patients Treated with Imatinib: Blood Level Testing of Imatinib in Nagoya (BINGO) Study. (2009) (0)
腸管移植関連微小血管障害(I‐TAM)の臨床病理学的所見および治療 (2009) (0)
Evaluation of Central Nervous System Recurrence of Intravascular Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy (2008) (0)
[Treatment of malignant tumors with autotransplantation of the bone marrow combined with high-dose chemotherapy]. (1983) (0)
[Association between serologic antibodies and infections to cytomegalovirus and herpes simplex virus in patients with allogeneic bone marrow transplantation]. (1983) (0)
Biomarkers In Cell Death of Imatinib-Resistant Ph-Leukemia Cells During Treatment with mTOR Inhibitor, Everolimus (2010) (0)
FOUR NOVEL CAUSATIVE MUTATIONS IDENTIFIED IN THE PROS1 GENE OF JAPANESE DEEP VEIN THROMBOSIS PATIENTS WITH PROTEIN S DEFICIENCY (2007) (0)
Potential Role of a Mismatched HLA-Specific Cytotoxic T Lymphocyte Clone Developed Pre-Transplant in Graft Rejection Following Cord Blood Transplantation. (2007) (0)
Analysis of Genomic Predispositions to Sporadic Myeloid Neoplasms Mediated By DDX41 in Japan (2018) (0)
Comprehensive Analysis of Genetic Alterations in Acute Myeloid Leukemia According to the WHO Classification. (2007) (0)
Post-azacitidine clone size predicts long-term clinical outcome of patients with myelodysplastic syndromes and related myeloid neoplasms (2021) (0)
Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation (2015) (0)
Clathrin Assembly Protein CALM Plays a Key Role In Erythroid Differentiation Via Regulating Transferrin Receptor Endocytosis (2010) (0)
137: Potential Role of a Mismatched HLA-Specific CTL Clone Developed Pre-Transplant in Graft Rejection Following Cord Blood Transplantation (2008) (0)
Adipocyte-Derived Stromal Cells Facilitate Hematopoiesis in Vitro and in Vivo: Advantages Over Bone Marrow-Derived Stromal Cells (2008) (0)
Rapid Reduction of Chronic Myeloid Leukemia Stem Cells After Treatment with Second-Generation BCR-ABL Kinase Inhibitors, Dasatinib and Nilotinib (2010) (0)
Increased Risk for Treatment-Related Mortality of Bone Marrow Transplantation in GSTM1 -Positive Recipients. (2005) (0)
[Granulocyte collection with high molecule HES (HM 30) into 2 alternative bags]. (1981) (0)
Prospective Evaluation of Prognostic Relevance of Gene Mutations and Minimal Residual Disease in Acute Myeloid Leukaemia with RUNX1-RUNX1T1 or CBFB-MYH11 (2019) (0)
Author reply (2006) (0)
Usefulness of Peripheral Blood Circulating DNAs As an Alternative to DNA From Bone Marrow Cells to Detect CpG Global Methylation Status and Genetic Mutations in Patients with Myelodysplastic Syndromes (2012) (0)
Looking Back at the 30th Nagoya International Cancer Treatment Symposium (2015) (0)
PAX5 Tyrosine Phosphorylation By Syk Co-Operatively Works with Its Serine Phosphorylation By ERK1/2 and Cancels PAX5-Dependent Repression of BLIMP1: A Mechanism of Antigen-Triggering Plasma Cell Differentiation through B Cell Receptor Signal (2014) (0)
[Clinical study of 4 patients with hematological malignancy treated with allogeneic bone marrow transplantation after conditioning including hyperfractionated total body irradiation]. (1987) (0)
Normal Karyotype-Acute Myeloid Leukemia With The CD4- CD7+ CD15+ CD34+ Immunophenotype Is a Clinically Distinct Entity With a Favorable Outcome (2013) (0)
Donor Single Nucleotide Polymorphism in the CCR9 Gene Affects the Incidence of Acute Skin Graft-Versus-Host Disease (2008) (0)
The Genotype Consisting of Complex Karyotype and TP53 Gene Mutation Is Specific to Acute Myeloid Leukemia with Multilineage Dysplasia (2008) (0)
Development of a novel humanized anti-CD20 chimeric antigen receptor; Effect on the CD20 down-regulated and mAb therapy resistant tumor cells (2015) (0)
Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O (2015) (0)
Study postremission therapy for acute myeloid leukemia in adults : the JALSG chemotherapy versus 3 courses of high-dose cytarabine alone in A randomized comparison of 4 courses of standard-dose multiagent (2011) (0)
Clonal Heterogeneity and Evolution of Acute Myeloid Leukemia During Disease Progression (2014) (0)
Outcome by Treatment Including An Intensified Consolidation Program with Dose-Escalated Doxorubicin for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Study by the Japan Adult Leukemia Study Group (JALSG ALL97 study). (2009) (0)
Wnt signaling is associated with cell survival in the interaction between acute myeloid leukemia cells and stromal cells (2016) (0)
Analysis of the Constitutively Active Wild-Type FLT3 Kinase Mediating Signaling. (2005) (0)
Treatment with the PI3K/mTOR Inhibitor, NVP-BEZ235, Overcomes Resistance to Imatinib in Quiescent or T315I-Mutated Ph+ Leukemia Cells, (2011) (0)
CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness (2011) (0)
[Animal models of MYH9 disorders]. (2013) (0)
[Clinical features of adult patients with acute lymphocytic leukemia according to immunological phenotypes of lymphoblasts (author's transl)]. (1979) (0)
Transformation of E2A-Deficient Pluripotent Progenitors by BCR-ABL Generates Imatinib-Resistant Leukemic Stem Cells. (2008) (0)
A CASE OF DELAYED ERYTHROPOIESIS AFTER BONE MARROW TRANSPLANTATION FROM AN ABO-COMPATIBLE SIBLING DONOR FOR ACQUIRED CHRONIC PURE RED CELL APLASIA (2017) (0)
Peptide-Dependency of Alloreactive T Cell Clones after HLA-Mismatch Hematopoietic Stem Cell Transplantation. (2007) (0)
ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study (2015) (0)
Efficacy and Safety of Micafungin as An Empirical Antifungal Therapy for Suspected Fungal Infection in Patients with Hematological Disorders. (2008) (0)
MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab. (2009) (0)
[Clinical application of Ommaya reservoir for adult central nervous system leukemia (author's transl)]. (1981) (0)
[Efficacy of granisetron, a 5-HT3 antagonist, in the prevention of nausea and vomiting induced by conditioning for hematopoietic stem cell transplantation]. (1998) (0)
Outcome of Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis: Retrospective Study of JALSG AML201 (2016) (0)
A New Era of Cancer Genome: 30th Nagoya International Cancer Treatment Symposium, Nagoya, February 2015: Proceedings (2015) (0)
-positive acute lymphoblastic leukemia BCR-ABL diagnosed high-quality complete remission for a majority of patients with newly Combination of intensive chemotherapy and imatinib can rapidly induce (2009) (0)
[All-trans retinoic acid therapy in acute promyelocytic leukemia--current status and prospect]. (1996) (0)
PS1344 PHASE 1/2 STUDY OF DSP-7888 IN PATIENTS WITH HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AFTER FAILURE OF AZACITIDINE (AZA) THERAPY (2019) (0)
ORIGINAL ARTICLE GATA-1 and GATA-2 binding to 3 0 enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines (2009) (0)
Title Phase I trial of volasertib , a Polo-like kinase inhibitor , in Japanese patientswith acute myeloid leukemia (2018) (0)
Engraftment Rate and Kinetics Following Umbilical Cord Blood Transplantation Is Critically Affected by CD34+ Progenitor Cell Dose and CD8+ T-Cell Dose Complementary. (2006) (0)
[Case of acute monocytic leukemia brought to the second remission by allogeneic bone marrow transplantation but eventually developing subcutaneous blastoma]. (1983) (0)
8. Hematopoietic Stem Cell Transplantation (2013) (0)
B Cell Receptor-ERK1/2 Signal Cancels PAX5-Dependent Repression of BLIMP1 Probably Through PAX5 Phosphorylation: A Mechanism of Antigen-Triggering Plasma Cell Differentiation (2011) (0)
Characterization Of CTL Clones Isolated From Bone Marrow Transplant Recipient With HLA-Cw-Mismatched Donor (2009) (0)
Rituximab Sensitivity to De Novo DLBCL Cells Showing the Specific Phenotype of CD20 Protein Immunohistochemistry-Positive / Flow Cytometory-Negative: Analyses of Its Clinical Significances and the Molecular Mechanisms. (2012) (0)
Prognostic Implication and Biological Roles of RhoH in Acute Myeloid Leukemia. (2007) (0)
Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3-ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study (2019) (0)
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide (2023) (0)
Leukemia Escape From HLA-Specific T Lymphocyte Pressure in a Recipient of HLA One Locus-Mismatched Bone Marrow Transplantation (2011) (0)
Improved Survival of Intravascular Large B-Cell Lymphoma (IVLBCL) by Rituximab Containing Combination Chemotherapies. (2007) (0)
Mast Cells As a Therapeutic Target for Hodgkin Lymphoma: Bortezomib Inhibits Mast Cell-Induced Modification of the Tumor Microenvironment (2012) (0)
Incidence and Clinical Features of Core Binding Factor Acute Myeloid Leukemia: A Collaborative Study of the Japan Adult Leukemia Study Group and the Korean Society of Hematology. (2012) (0)
Characterization of immunoglobulin heavy chain gene rearrangements in chronic myeloid leukemia with recurrent B-lymphoid blast crisis following bone marrow transplantation. (1994) (0)
Prognostic Analysis According to the 2017 ELN Risk Stratification by Genetics in Adult Acute Myeloid Leukemia Patients Treated in The Japan Adult Leukemia Study Group (JALSG) AML201 study: AML‐052 (2018) (0)
Treatment with Bortezomib Overcomes Resistance to Imatinib in Ph-Leukemia Quiescent Cells. (2009) (0)
Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML (2022) (0)
MicroRNAs 143 and 145 are onco-related miRNAs in human colon cancers (2008) (0)
A New Stratification System for Adult AML That Includes FLT3-ITD as a Prognostic Factor-A JALSG Study. (2006) (0)
Ocular Adnexal Lymphomas: Experience of Single Center (2015) (0)
Phase III Randomized Study of Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Comparing Standard Dose-Escalation with Progressive Dose-Escalation (JALSG CML207 study) (2016) (0)
Open Access SHORT COMMUNICATION (2010) (0)
[Characterization of the immunoglobulin heavy and light chain variable region sequences from human multiple myeloma cells]. (1995) (0)
O1-6-4NANOG expression as a responsive biomarker during treatment with Hedgehog signal inhibitor in acute myeloid leukemia (2016) (0)
Issue Information (2020) (0)
Optimization of Fludarabine + Melphalan Conditioning for Marrow Transplantation From Unrelated Donors for Patients with Hematopoietic Malignancies: A Prospective Dose-Finding Trial Using Modified Continual Reassessment Method. (2009) (0)
Retention of Slow-Cycling CD34+ cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph+ Leukemia Cells (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Tomoki Naoe?

Tomoki Naoe is affiliated with the following schools:

Nagoya University